These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 22321826)

  • 1. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
    Pereira CD; Azevedo I; Monteiro R; Martins MJ
    Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Stimson RH; Walker BR
    Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
    Wamil M; Seckl JR
    Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
    Lloyd DJ; Helmering J; Cordover D; Bowsman M; Chen M; Hale C; Fordstrom P; Zhou M; Wang M; Kaufman SA; Véniant MM
    Diabetes Obes Metab; 2009 Jul; 11(7):688-99. PubMed ID: 19527482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
    Morton NM; Seckl JR
    Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease.
    Morton NM
    Mol Cell Endocrinol; 2010 Mar; 316(2):154-64. PubMed ID: 19804814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
    Schnackenberg CG
    Curr Opin Investig Drugs; 2008 Mar; 9(3):295-300. PubMed ID: 18311666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
    Nuotio-Antar AM; Hachey DL; Hasty AH
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1517-28. PubMed ID: 17878220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
    Alberti L; Girola A; Gilardini L; Conti A; Cattaldo S; Micheletto G; Invitti C
    Int J Obes (Lond); 2007 Dec; 31(12):1826-31. PubMed ID: 17593901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
    Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
    Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cortisol--cause and cure for metabolic syndrome?
    Walker BR
    Diabet Med; 2006 Dec; 23(12):1281-8. PubMed ID: 17116176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
    Wang M
    Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 11β-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus.
    Hollis G; Huber R
    Diabetes Obes Metab; 2011 Jan; 13(1):1-6. PubMed ID: 21114597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
    Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Dhote V; Sharma A; Jain M
    Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):69-77. PubMed ID: 22060140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease.
    Candia R; Riquelme A; Baudrand R; Carvajal CA; Morales M; Solís N; Pizarro M; Escalona A; Carrasco G; Boza C; Pérez G; Padilla O; Cerda J; Fardella CE; Arrese M
    Liver Int; 2012 Mar; 32(3):392-9. PubMed ID: 22136330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 11-Dehydrocorticosterone causes metabolic syndrome, which is prevented when 11β-HSD1 is knocked out in livers of male mice.
    Harno E; Cottrell EC; Keevil BG; DeSchoolmeester J; Bohlooly-Y M; Andersén H; Turnbull AV; Leighton B; White A
    Endocrinology; 2013 Oct; 154(10):3599-609. PubMed ID: 23832962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
    Iwasaki Y; Takayasu S; Nishiyama M; Tsugita M; Taguchi T; Asai M; Yoshida M; Kambayashi M; Hashimoto K
    Mol Cell Endocrinol; 2008 Mar; 285(1-2):10-8. PubMed ID: 18313835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
    Livingstone DE; Walker BR
    J Pharmacol Exp Ther; 2003 Apr; 305(1):167-72. PubMed ID: 12649365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
    Tomlinson JW
    Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.
    Walker BR; Andrew R
    Ann N Y Acad Sci; 2006 Nov; 1083():165-84. PubMed ID: 17148739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.